Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-8.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -210.50% |
| Return on Assets (Trailing 12 Months) | -99.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.34 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-6.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-66.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-41.45 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 0.59M |
| Free Float | 0.51M |
| Market Capitalization | $4.34M |
| Average Volume (Last 20 Days) | 4236.35 |
| Beta (Past 60 Months) | 1.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.46% |
| Percentage Held By Institutions (Latest 13F Reports) | 8.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |